IBRX — ImmunityBio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1326110 ·
Last close
$6.26
Market Cap
$6.66B
52W High
$12.43
52W Low
$1.95
ADV30
14,214,052
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 48,841,000 | 47,550,000 | -77,987,000 | -184,550,000 | 609,391,000 | 45,082,000 | 1,754,831,000 |
| Jun 2026 | 51,240,000 | 50,942,000 | -61,697,000 | -230,378,000 | 628,504,000 | 75,670,000 | 1,674,265,000 |
| Mar 2026 | 44,206,000 | 43,968,000 | -69,791,000 | -632,782,000 | 646,637,000 | 205,194,000 | 1,515,763,000 |
| Dec 2025 | 38,285,000 | 37,903,000 | -64,683,000 | -61,944,000 | 501,898,000 | 88,334,000 | 1,001,472,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-287,564,000
Investing CF
$-103,589,000
Financing CF
$376,297,000
CapEx
$-9,528,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-1.08
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-4,774,356,000
Inventory
$6,000
Receivables
$53,611,000
ST Investments
$289,247,000
EBIT TTM
$-990,919,000
Pretax Income TTM
$-1,109,836,000
Interest Exp TTM
$118,917,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$182,572,000
EBITDA
$-257,716,992
Free Cash Flow
$-176,333,872
Enterprise Value
$7,366,854,144
Total Cash
$334,328,992
Total Debt
$1,296,097,024
Shares Out
1,063,826,073
Trailing EPS
$-1.06
Book Value
$-1.08
ROE
—
ROA
-30.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 113,288,000 | -256,027,000 | -351,398,000 | 501,898,000 | 1,001,472,000 | -500,469,000 | -304,936,000 |
| Dec 2024 | 14,745,000 | -344,182,000 | -413,564,000 | 382,933,000 | 871,062,000 | -489,098,000 | -391,236,000 |
| Dec 2023 | 622,000 | -361,364,000 | -583,196,000 | 504,452,000 | 1,090,389,000 | -586,987,000 | -366,757,000 |
| Dec 2022 | 240,000 | -350,617,000 | -416,567,000 | 362,356,000 | 812,176,000 | -447,327,000 | -337,509,000 |
TTM Snapshot
Revenues TTM
$165,792,000
NetIncome TTM
$-992,357,000
OpCashFlow TTM
—
Assets (Latest)
$628,504,000
Forward EPS
$-0.11
Max Pain — expiry 2026-11-27
max pain strike: $7.00 · spot: $6.70 · call oi: 2,477 · put oi: 2,528
Expected Move to 2026-11-27:
±$1.43
(21.27%) —
implied range
$5.28 –
$8.12
· ATM straddle on $6.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMVT | Immunovant, Inc. | $6.87B | $33.21 | — |
| CGON | CG Oncology, Inc. | $7.00B | $78.94 | — |
| KOD | Kodiak Sciences Inc. | $6.33B | $96.80 | — |
| TWST | Twist Bioscience Corp | $7.43B | $112.00 | — |
| SRRK | Scholar Rock Holding Corp | $5.50B | $45.08 | — |
News headlines (Yahoo Finance, 1h cache)
IBRX CEO Reveals Fresh Anktiva Data After Bladder Cancer Trial Win — Says FDA Filing Is Just Weeks Away
2026-11-17 06:38 · Yahoo
SLS, IBRX And IOVA Join Merck And Lilly On BlackRock’s Q3 Buy List — A Vanguard Unit Adds All Of Them Too
2026-11-16 07:31 · Yahoo
IBRX Stock In Focus As Institutional Investor Boosts Stake By Over 15% In Q3 — All Eyes On ImmunityBio’s London Conferences Next Week
2026-11-13 17:28 · Yahoo
IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth’ NantWorks Reveals — Cancer Tech, AI Chips And Satellites
2026-11-13 01:20 · Yahoo
ImmunityBio (IBRX) is Declining For 4 Days Now. What’s Triggering the Selloff?
2026-11-13 00:48 · Yahoo
IBRX Stock Eyes Worst Week In Nearly 2 Years — But Anktiva’s Sepsis Trial Potential Fuels Retail Bets On Big Pharma Appeal
2026-11-12 03:52 · Yahoo
What Could ImmunityBio (IBRX) Gain From ANKTIVA Label Expansion And Global Rollout?
2026-11-12 02:15 · Yahoo
ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026
2026-11-11 02:31 · Yahoo
ImmunityBio shares slump 19% as revenue misses and going-concern warning hits sentiment
2026-11-09 16:44 · Yahoo
IBRX Stock Crashes To Near 9-Month Lows On Q3 Earnings Miss – Retail Says No Way To Escape Further Dilution
2026-11-09 14:36 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.